Video Experimental Relacionado
Updated: Sep 8, 2026
10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
CVS-1123 eficaz por vía oral previene la trombosis de la arteria coronaria en el perro consciente
G R Cousins1, G S Friedrichs, Y Sudo
1Department of Pharmacology, University of Michigan Medical School, Ann Arbor 48109-0632, USA.
Circulation
|October 1, 1996
Resumen
El inhibidor directo de la trombina oral CVS-1123 evitó eficazmente la trombosis de la arteria coronaria en perros después de una lesión arterial. Este estudio destaca CVS-1123 como un agente antitrombótico potencial para uso clínico.
Área de la Ciencia:
- Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular
- Farmacología Farmacología.
- Investigación de la trombosis.
Sus antecedentes:
- Investigó la eficacia oral de CVS-1123, un inhibidor directo de la trombina.
- Se evaluó el potencial de la inhibición de la trombina para reducir la trombosis de la arteria coronaria oclusiva después de una lesión arterial.
Objetivo del estudio:
- Para determinar si la administración oral de CVS-1123 podría prevenir la trombosis arterial.
- Para evaluar la eficacia de CVS-1123 en un modelo canino de lesión de la pared arterial.
Principales métodos:
- Los perros conscientes recibieron por vía oral CVS-1123 (20 mg/kg) o placebo antes de inducir una lesión en la pared arterial.
- La permeabilidad de la arteria coronaria fue monitoreada durante 24 horas después de la lesión.
- Se midieron las concentraciones plasmáticas del fármaco y la agregación plaquetaria ex vivo.
Principales resultados:
- 8 de 11 perros tratados con CVS-1123 mantuvieron la permeabilidad de la arteria coronaria.
- Los 10 perros tratados con placebo desarrollaron trombo arterial oclusivo.
- CVS-1123 inhibió la agregación plaquetaria y prolongó el tiempo de tromboplastina parcial activado.
Conclusiones:
- El CVS-1123 oral redujo efectivamente la formación de trombos en un modelo experimental de lesión arterial.
- Los inhibidores específicos de la trombina como CVS-1123 pueden ofrecer alternativas a la heparina.
- CVS-1123 se muestra prometedor para la terapia anticoagulante a largo plazo.
Videos de Conceptos Relacionados
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...